The decision paves the way for young people with relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL) to access Novartis’ Kymriah (tisagenlecleucel) through the Cancer Drugs Fund (CDF).
NHS England is now preparing to make the CART cell therapy, which involves taking a person’s own immune cells and modifying them to fight their cancer cells, available to patients under 25 years who have not responded to current treatment or who have relapsed after stem cell transplant.
Around 25 to 30 people will be eligible for treatment with Kymriah each year in England, and a specialised NHS service is being developed to manage access to the new therapy.
NHS England reached a commercial agreement for the treatment with Novartis back in September, facilitating NICE’s CDF recommendation.
“NICE’s recommendation of tisagenlecleucel marks a new generation of personalised medicine that has the potential to transform the care of patients with cancer worldwide,” noted Meindert Boysen, director of the Centre for Health Technology Evaluation at NICE…